About - APTO :

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Employees - 35, CEO - Dr. William G. Rice Ph.D., Sector - Healthcare, Country - CA, Market Cap - 16.61M

Altman ZScore(max is 10): -10.4, Piotroski Score(max is 10): 1, Working Capital: $477000, Total Assets: $10929000, Retained Earnings: $0, EBIT: -36448931, Total Liabilities: $20063000, Revenue: $712206

- Current Price $0.28 - Analyst Target Price $2.00

Stats & Key Metrics
TickerAPTO
Index-
Curent Price 0.28
Change63.92%
Market Cap16.61M
Average Volume6.04M
Income-35.80M
Sales0.00M
Book Value/Share-0.47
Cash/Share0.13
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees35
Moving Avg 20days45.81%
Moving Avg 50days-6.83%
Moving Avg 200days-61.44%
Shares Outstanding59.52M
Earnings DateNov 08 AMC
Inst. Ownership5.43%
Key Ratios & Margins
Price/Earnings-
Forwad P/E-
PE Growth-
Price/Sales-
Price/Book-
Price/Cash2.09
Price/FCF-
Quick Ratio1.05
Current Ratio1.05
Debt/Equity-
Return on Assets-225.12%
Return on Equity-694.13%
Return on Investment-3057.22%
Gross Margin-
Ops Margin-
Profit Margin-
RSI60.81
BETA(β)0.83
From 52week Low114.62%
From 52week High-89.59%
Earnings & Valuation
EPS-3.05
EPS next Year-
EPS next Qtr-0.35
EPS this Year76.39%
EPS next 5 Year-
EPS past 5 Year10.18%
Sales past 5 Year0.00%
EPS Y/Y61.28%
Sales Y/Y-
EPS Q/Q78.74%
Sales Q/Q-
Sales Surprise-
EPS Surprise-
ATR(14)0.04
Perf Week44.56%
Perf Month2.16%
Perf Quarter-32.67%
Perf Year-88.03%
Perf YTD-89.02%
Target Price2.00

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer